AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 14-E-03-048.03
CMS should explore the possibility of conducting descriptive analyses of Part B claims for compounded drugs.
The publisher's file lists March 10, 2023 as the date the next update was expected. That date has passed. This is the publisher's own date field, not a finding that anyone missed a deadline.
The recommendation, in the publisher's words
CMS should explore the possibility of conducting descriptive analyses of Part B claims for compounded drugs.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- April 29, 2014
- Report
- Compounded Drugs Under Medicare Part B: Payment and Oversight (OEI-03-13-00270) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Concur (as recorded by the publisher)
- Last update received
- February 24, 2022
- Next update expected
- March 10, 2023 (publisher's date)
- Publisher topics
- Food; Drug and Device Safety, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
1 more, of which 0 are open in the publisher's file.
- CMS should explore the possibility of requiring providers to identify on the Part B claim the pharmacy that produced the compounded drug.HHS OIG 14-E-03-048.02 · issued Apr 29, 2014 · closed Mar 22, 2024Closed Unimplemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.